Equities

NeuPath Health Inc

NPTH:CVE

NeuPath Health Inc

Actions
Health CareHealth Care Providers
  • Price (CAD)0.18
  • Today's Change0.00 / 0.00%
  • Shares traded64.00k
  • 1 Year change+16.13%
  • Beta0.5152
Data delayed at least 15 minutes, as of Sep 19 2024 15:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year NeuPath Health Inc grew revenues 5.50% from 62.65m to 66.10m while net income improved from a loss of 4.14m to a smaller loss of 107.00k.
Gross margin19.04%
Net profit margin0.01%
Operating margin-0.04%
Return on assets0.01%
Return on equity-0.34%
Return on investment0.02%
More ▼

Cash flow in CADView more

In 2023, NeuPath Health Inc increased its cash reserves by 109.43%, or 1.66m. The company earned 3.03m from its operations for a Cash Flow Margin of 4.58%. In addition the company generated 1.59m cash from investing, though they paid out 2.96m more in financing than they received.
Cash flow per share0.0444
Price/Cash flow per share4.05
Book value per share0.3908
Tangible book value per share0.0098
More ▼

Balance sheet in CADView more

NeuPath Health Inc has a Debt to Total Capital ratio of 34.77%, a lower figure than the previous year's 44.50%.
Current ratio1.03
Quick ratio--
Total debt/total equity0.5303
Total debt/total capital0.3477
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.